<DOC>
	<DOCNO>NCT00051129</DOCNO>
	<brief_summary>The purpose study evaluate anecortave acetate compare placebo maintenance visual acuity 24 month treatment patient subfovial choroidal neovascularization ( CNV ) due exudative age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>Anecortave Acetate Subfoveal Choroidal Neovascularization ( CNV ) Due Wet Age-Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Anecortave</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Diagnosis exudative AMD primary recurrent subfoveal CNV lesion study eye . Other protocoldefined inclusion criterion may apply . Under 50 year . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>AMD</keyword>
	<keyword>anecortave acetate</keyword>
	<keyword>wet AMD</keyword>
	<keyword>age-related macular degeneration</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>Maculopathy , Age-Related</keyword>
	<keyword>Age-Related Maculopathies</keyword>
	<keyword>Age-Related Maculopathy</keyword>
	<keyword>Maculopathies , Age-Related</keyword>
</DOC>